ImmunityBio (IBRX) 8-K Summary

Filing Date: November 4, 2025

This 8-K primarily reports the issuance of a press release detailing financial results and a business update for the third quarter and nine months ended September 30, 2025.

• Key Disclosure: Item 2.02 references Exhibit 99.1, which contains the specific Q3 2025 financial data and business highlights.
• Status: The report furnishes (does not deem “filed”) this information, limiting liability under Section 18 of the Exchange Act unless expressly incorporated elsewhere.
• Management: Signed by David C.